Mirabegron alone or in combination with solifenacin succinate 5 mg can increase blood pressure. Periodic blood pressure determinations are recommended, especially in hypertensive patients. Mirabegron is not recommended for use in severe uncontrolled hypertensive patients.
- TRADE NAMES: Betanis; Myrbetriq (Astellas)
- INDICATIONS: Overactive bladder
- CLASS: Beta-3 adrenergic agonist
- HALF-LIFE: 50 hours
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Antimuscarinics, Desipramine, Digoxin, Flecainide, Metoprolol, Propafenone, Thioridazine
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of mirabegron in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 08/20/2025
